Earnings ·
Immunocore reports Q3 net revenues of $102.2M and a net loss of $14.2M
IMCRImmunocore Holdings plc
Immunocore Holdings plc reported third-quarter 2026 financial results with KIMMTRAK net product revenue of $102.2 million, down slightly from $103.7 million in the prior-year period due to wholesaler stocking and calendar effects; underlying growth was approximately 10%. For the nine months ended September 30, 2026, net sales reached $324.8 million, up from $295.5 million. The company posted a net loss of $14.2 million ($0.28 per share) for Q3 compared to a near-breakeven result in the same quarter last year. Cash and marketable securities stood at $901.3 million as of September 30, 2026. The Phase 3 TEBE-AM trial for advanced cutaneous melanoma has completed enrollment with top-line data expected in Q2 2027. Immunocore is a commercial-stage biotechnology company developing TCR bispecific immunotherapies for cancer, infectious diseases, and autoimmune conditions.